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 Introduction 
On behalf of the Swiss Society of Dermatology and Ve-
nereology SGDV/SSDV, the Swiss Dermatology Network 
for Targeted Therapies has prepared an evidence-based 
guideline for the treatment of plaque-type psoriasis. This 
work is partially based on previously published Swiss rec-
ommendations  [1, 2] , the updated German S3 guidelines 
 [3] and the European S3 guideline for psoriasis  [4] . The 
goal of the Swiss S1 guidelines is to develop an informal 
expert consensus to provide a strategy management of sys-
temic therapies by Swiss dermatologists and to focus on 
induction therapy in cases of moderate-to-severe plaque-
type psoriasis in adults, as well as to include useful Swiss-
specific aspects and regulatory issues. The varieties of a pa-
tient’s disease aspects with their medical history, therapy 
preferences, comorbidities including psoriatic arthritis, 
childbearing potential, risk of infection, adherence, long-
term safety and much more are major points in the deci-
sion between patients and their treating physicians to 
choose the right medication to treat psoriasis and have to 
be evaluated in the individual patient’s consultation.
 In Western industrialized nations, psoriasis has a 
prevalence of 1.5–2%. About 80% of those afflicted suffer 
from the plaque form, and more than 90% are chronic  [5] . 
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 Abstract 
 Psoriasis vulgaris is a common, chronic inflammatory skin 
disease with a prevalence of 1.5–2% in Western industrial-
ized countries. A relevant percentage of patients suffer from 
moderate-to-severe psoriasis and experience a significant 
reduction in quality of life. The choice of an adequate thera-
py could help to prevent disease and exacerbation of comor-
bidity, which could increase quality of life, avoid hospital-
ization and avoid reduction of working days. The present 
guidelines are focused on the initiation and management of 
systemic therapies in cases of moderate-to-severe plaque-
type psoriasis in adults to optimize treatment response, ad-
herence and quality of life. This first version of the Swiss S1 
guidelines presents therapeutic recommendations which 
are based on a systematic literature search as well as an in-
formal expert consensus of dermatologists in Switzerland. 
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Depending on the severity of disease and related disabil-
ity as well as psychosocial stigmatization, the quality of 
life can be considerably impaired  [6] , comparable to pa-
tients with type 2 diabetes, cancer and chronic lung dis-
ease  [7] . Nevertheless, in the past, adherence to therapies 
was observed to be relatively low. Before the advent of 
biological therapies, only 25% of patients were very satis-
fied with the results of their therapy for psoriasis  [8] , re-
sulting in a high rate of nonadherence of up to 40%  [9, 
10] . In addition, patients reported lack of information 
about potential side effects of drugs, complicated usage, 
poor tolerability, fear, costs, and low efficacy  [11, 12] . 
Dermatologists have high expertise in managing topical 
drugs, but 76% are somewhat uncertain about prescribing 
systemic medications  [13] . Thus, about 50% of moderate-
to-severe psoriasis patients are treated with topicals alone 
 [14] . However, the choice of an adequate therapy could 
help to prevent disease and exacerbation of comorbidity 
which could increase quality of life, avoid hospitalization 
and avoid reduction of working days, which is also recog-
nized by the World Health Organization  [15, 16] .
 Systemic Treatment Options in Moderate-to-Severe 
Chronic Plaque Psoriasis 
 Moderate-to-severe psoriasis is defined as Psoriasis 
Area and Severity Index (PASI) >10 or body surface area 
(BSA) >10% and/or Dermatology Life Quality Index 
(DLQI) >10  [17] . The Swiss guideline expert panel unan-
imously supports this definition and urges insurances 
and policy makers to accept DLQI >10 as official thresh-
old.
 This becomes important in severe involvement of spe-
cial locations, particularly in areas such as the scalp, gen-
itals, palms and/or soles, nail involvement, presence of 
single recalcitrant plaques or pruritus leading to scratch-
ing. Severe involvement of visible areas but not high BSA 
is not reflected by representative values of the PASI. Lo-
calized tools like palmoplantar PASI (online suppl. calcu-
lator; see www.karger.com/doi/10.1159/000445681 for all 
online suppl. material)  [18] and Nail Psoriasis Severity 
Index  [19] have been suggested but are not generally used 
for severity assessment in special localizations. Especially 
nail, palmoplantar and inguinal involvement has a severe 
impact on quality of life. Here the DLQI should be con-
sidered for the evaluation of the psoriasis severity.
 The PASI is a standard tool to define disease severity 
in psoriasis as well as the BSA, DLQI, Physician’s Global 
Assessment or Investigator’s Global Assessment  [20–23] . 
An adapted PASI calculation, the Precise PASI, utilizes 
the same source data as the PASI but does not neglect the 
percentages of surface involvement, achieving a much 
higher resolution in the lower BSA ranges (<5%)  [24] .
 The current systemic treatment options in Switzerland 
for moderate-to-severe psoriasis include small molecules 
and biologicals. The former group encompasses small 
molecules such as methotrexate (MTX), cyclosporine A 
(CsA), apremilast (APR), fumaric acid esters (FAEs) and 
aci tretin. The latter group includes the tumor necrosis fac-
tor (TNF)-α antagonists adalimumab (ADA), etanercept 
(ETA), and infliximab (IFX), the p40 interleukin (IL)-
12/23 antagonist ustekinumab (UST) and the IL-17A an-
tagonist secukinumab (SEC). FAEs are not formally reg-
istered for the treatment of psoriasis in Switzerland.
 Before any of the above treatments are prescribed, ex-
ternal skin care and topical drugs should be used to the 
fullest extent, namely emollients, topical drugs such as 
corticosteroids, vitamin D derivates and tacrolimus/
pimecrolimus, as well as phototherapy such as narrow-
band UVB, UVA or topical/systemic PUVA. These are 
often additionally used in moderate-to-severe psoriasis as 
a first-line treatment. Only when insufficient efficacy of 
these treatments is confirmed, systemic agents should be 
used. In Switzerland biologicals can be used exclusively in 
patients who were unsuccessfully treated with at least one 
conventional systemic therapy and/or phototherapy 
(limitation for biologicals by insurance/governmental 
regulations). In addition, IFX is reimbursed only after 
failure of a previous TNF-α inhibitor and a treatment du-
ration of 1 year but can be extended by permission of the 
insurance in case of positive treatment success.
 Acitretin 
 Acitretin is a retinoid (vitamin A derivate) that can be 
used for moderate-to-severe psoriasis vulgaris, as well as 
local or generalized pustular or erythrodermic psoriasis. 
In contrast to other systemic therapies, it is not consid-
ered cytotoxic or immunosuppressive. This is considered 
an advantage for patients with malignant tumors. Also, it 
has an antiproliferative effect that is partially preventive 
for epithelial tumors of the skin  [5, 25, 26] .
 Induction therapy for plaque psoriasis is started with 
10–20 mg/day (0.3–0.5 mg/day/kg body weight) for 4 
weeks, and then slowly increased until patients notice a 
slight scaliness on the lips which is an indicator for suf-
ficient bioavailability. The general maintenance dose is 
recommended between 25 and 50 mg/day (0.5–0.8 mg/kg 
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body weight) depending on efficacy and tolerability. Dos-
es up to 20 mg daily do not usually lead to a satisfactory 
response but have no or only mild side effects  [26] . Cap-
sules should be ingested with whole milk or a fatty meal. 
Combination therapies have been described with UV 
phototherapy (narrow-band UVB, broad-band UVB, 
UVA and PUVA) as well as MTX, cyclosporine, TNF in-
hibitors and UST  [27] .
 Because of the high teratogenicity, double contracep-
tion is mandatory for women during and up to 2 years 
after discontinuation (e.g. condom + pill; intrauterine de-
vice/Nuva-Ring + pill; please note:  no low-dosed proges-
terone preparations/minipills). Monthly pregnancy tests 
are recommended in women of childbearing age; see  ta-
ble 2 for the prevention of adverse events  [5] . The patient 
should be asked about spine/joint complaints at follow-
up visits; if yes without a hint for psoriatic arthritis (PsA), 
further imaging should be performed due to the possibil-
ity of diffuse idiopathic skeletal hyperostosis which oc-
curs in less than 1% of patients. Depression is not listed 
as an official side effect in patients treated with acitretin 
but is described very rarely.
 Headache, nausea and/or vomiting, fatigue, irritabili-
ty, and pruritus are symptoms of acute overdose. In this 
case, discontinue retinoids, monitor vital parameters/liv-
er and renal function/electrolytes and consult specialists 
to manage extracutaneous side effects ( tables 1, 2 ).
 Absolute Contraindications 
 • Severe renal or hepatic dysfunction 
 • Hepatitis 
 • Women of childbearing age: pregnancy, breast-feed-
ing, desire to have children or insufficient guarantee of 
effective contraceptive measures up to 2 years after 
discontinuation of therapy 
 • Excessive alcohol consumption 
 • Incompatible comedication 
 • Unwillingness to cease blood donation during and un-
til 1 year after treatment 
 • Hypersensitivity to acitretin 
 Relative Contraindications 
 • Alcohol abuse 
 • Diabetes mellitus 
 • Contact lenses 
 • Childhood 
 • History of pancreatitis 
 • Hyperlipidemia (particularly hypertriglyceridemia) 
and drug-controlled hyperlipidemia 
 • Atherosclerosis 
 Limitation (FOPH) 
 Severe, therapy-refractory cases of psoriasis [as limita-
tion, reimbursement criteria of the Federal Office of Pub-
lic Health (FOPH, in German Bundesamt für Gesund-
heit, BAG) are considered].
 Apremilast 
 Apremilast (APR, Otezla ® ) is a small molecule inhibit-
ing intracellular phosphodiesterase-4. It is indicated in 
patients with moderate-to-severe plaque psoriasis who 
failed light therapy, MTX, cyclosporine, acitretin or 
PUVA and is also indicated in psoriatic arthritis patients 
 Table 1.  Overview of important side effects of acitretin [27, 30]
Frequency Side effects
Very frequent Vitamin A toxicity (xerosis, cheilitis)
Frequent Conjunctival inflammation (check contact 
lenses), hair loss, photosensitivity, 
hyperlipidemia
Occasional Muscle, joint, and bone pain, retinoid dermatitis
Rare Gastrointestinal complaints, hepatitis, jaundice, 
bone changes with long-term therapy
Very rare Idiopathic intracranial hypertension, decreased 
color vision and impaired night vision
 Table 2.  Prevention of side effects of acitretin
Prevention of adverse 
events
Action
Dry skin or mucous 
membranes
Apply ointment (also to nasal mucosa 
if needed), eyedrops, avoid wearing 
contact lenses
Diffuse alopecia Inform patient of reversible nature of 
the side effect, consider stopping 
treament
Light sensitivity Avoid exposure to sunlight, use 
sunscreen
Increased serum lipids 
and/or liver values
Alcohol abstinence, low-fat/low-
carbohydrate diet, lipid-lowering 
drug (gemfibrozil or atorvastatin); if 
levels fluctuate: monitor frequency 
and discontinue therapy if necessary
Muscle and bone pain If symptoms persist: X-rays, NSAIDs, 
avoid excessive physical activity, 
consider PsA
Generalized edema (rare) Stop treatment, check kidney function
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who failed disease-modifying antirheumatic drugs ( ta-
ble 3 ).
 The recommended dosage is 30 mg p.o. twice daily for 
maintenance; see  table 4 for induction scheme.
 In case of infection during treatment, stop temporar-
ily. 
 Absolute Contraindications 
 • Rare hereditary problems of galactose intolerance, 
lapp lactase deficiency or glucose-galactose malab-
sorption 
 • Pregnancy/breast-feeding 
 • Hypersensitivity to apremilast 
 • Live vaccines 
 Relative Contraindications 
 • In patients with severe renal impairment (creatinine 
clearance of less than 30 ml/min estimated by the 
Cockcroft-Gault equation), the dose should be re-
duced to 30 mg once daily 
 • Caution in case of depression 
 • Underweight at the start of treatment should be mon-
itored regularly; in case of unexplained and clinically 
significant weight loss, evaluate the patient and con-
sider discontinuation of APR. 
 With lack of data or recommendations, the following 
medical states should be considered very carefully: active 
and latent tuberculosis, acute or severe infections, history 
of or active chronic hepatitis B and C, HIV, live vaccines, 
malignancies (apart from successfully treated nonmela-
noma skin cancer and cervical dysplasia) and lympho-
proliferative disorders. Diarrhea is rather transient over 
the first weeks of treatment.
 Limitation (FOPH) 
 Treatment of adults with severe plaque-type psoriasis 
who did not experience therapeutic success with UVB 
and PUVA or one of the following systemic therapies:
cyclosporine, MTX, acitretin. The treatment has to be 
stopped in case of no therapeutic success after 24 weeks. 
Not in combination with biologicals. For psoriasis it can 
only be prescribed by dermatologists or dermatological 
university hospitals/outpatient clinics.
 Cyclosporine A 
 CsA is indicated for moderate-to-severe psoriasis (as 
well as rescue therapy for erythrodermic and pustular 
psoriasis), especially in induction therapy  [29] . A combi-
nation with topical steroids and vitamin D analogs may 
be recommended and reduce the dosage of CsA. Due to 
side effects such as nephrotoxicity, increased cancer risk 
and arterial hypertension, therapy is limited to 1 year  [5] .
 CsA capsules contain 12.7% of alcohol which has to be 
taken into account in patients with liver diseases, alcohol 
abuse, epilepsy, brain injuries, pregnancy, breast-feeding 
women and children. CsA itself shows no teratogenicity 
but may be associated with preeclampsia, premature birth 
and low birth weight.
 There are a lot of possible interactions with other 
drugs, especially statins, with an increased risk of myopa-
thies. Side effects are possibly dose dependent and disap-
pear with dose reduction ( table 5 ).
 Table 3.  Overview of important side effects of apremilast [28]
Frequency Side effect
Very frequent Diarrhea, nausea
Frequent Bronchitis, upper respiratory tract infections, 
nasopharyngitis, decreased appetite, insomnia, 
migraine, (tension) headache, cough, 
vomiting, dyspepsia, frequent bowel 
movements, upper abdominal pain, 
gastroesophageal reflux disease, back pain, 
fatigue
Occasional Hypersensitivity, rash, weight decrease
Rare None
Very rare None
Frequency not 
reported (causal 
connection 
unclear)
Depression, urinary tract infection, coronary 
artery disease, acute myocardial infarction, 
chronic obstructive pulmonary disease, 
nephrolithiasis, osteoarthritis, psoriatic 
arthropathy, diverticulitis, pneumonia, basal 
cell carcinoma, squamous cell carcinoma, 
keratoacanthoma, breast cancer, renal cell 
carcinoma, vasculitis
 Table 4.  Dosing scheme (mg) for initiation of apremilast therapy
Day Morning Evening
Day 1 10 –
Day 2 10 10 
Day 3 10 20 
Day 4 20 20 
Day 5 20 30 
Day 6 and ongoing 30 30 
D
ow
nl
oa
de
d 
by
: 
Sp
ita
l N
et
z 
Be
rn
 A
G
   
   
   
   
   
   
   
   
   
   
   
   
16
1.
62
.2
52
.4
0 
- 1
/1
7/
20
17
 3
:5
1:
46
 P
M
 Swiss S1 Guidelines on Psoriasis Dermatology 2016;232:385–406
DOI: 10.1159/000445681
389
 The combination of CsA and excessive phototherapy 
leads to an increased risk of squamous cell carcinoma  [5] .
 Handling of Side Effects  [25] 
 • If serum creatinine is increased (5–30%, in up to 20% 
increase in creatinine by more than 30%): 
 –  ≤ 30% of baseline value should prompt a revision of the 
patient’s fluid intake 
 – 30–50% of baseline value (even if in the normal range), 
a dose reduction of 25% is recommended 
 –  ≥ 50% of baseline value should lead to a dose reduction 
of 50% 
 – If after 30 days an increase of  ≥ 30% persists, stop CsA; 
calculate creatinine clearance (reduced in up to 20% of 
patients) 
 • Arterial hypertension (2–5%) requires an antihyper-
tensive therapy if blood pressure is  ≥ 160/90 mm Hg 
in two consecutive measurements. However, calcium 
antagonists could raise CsA levels, and angiotensin-
converting enzyme inhibitors/angiotensin-2 recep-
tor antagonists could induce hyperpotassemia. If de-
spite an antihypertensive therapy the blood pressure 
is still increased, a CsA dose reduction of 25% is nec-
essary, with subsequent stop in case of insufficient 
response 
 • Hypomagnesemia (about 5–15%): substitute 200 mg/
day, possibly more 
 • Hyperpotassemia (>5.0 mmol/l): potassium-deficient 
nutrition, ensure sufficient fluid intake (2–3 l/day), re-
duce CsA by 25%, acute management of severe hyper-
potassemia ( ≥ 6.0 mmol/l) 
 • Elevation of bilirubin (10–80%) or transaminases (up 
to 30%) by twice the upper limit of normal should lead 
to a dose reduction by 25% and laboratory control af-
ter 30 days; if still elevated, consider CsA cessation 
 • Elevation of blood lipids (fasting cholesterol and tri-
glycerides) should be answered with a low-cholesterol- 
and low-fat diet, dose reduction, or stop of CsA, re-
spectively. Statins or fibrates are not recommended 
due to the risk of restriction of renal function and my-
algia to rhabdomyolysis 
 • Gingival hyperplasia (in up to 15%): optimal den-
tal hygiene, dose reduction, if persistent, stop CsA. 
More frequent in case of concomitant nifedipine 
treatment 
 Interactions 
 There are several interactions that need to be checked 
before initiation of treatment. CsA can reduce the ef-
ficacy of progesterone-containing contraceptives. Suffi-
cient contraception has to be ensured.
 • Increase in the cyclosporine level (CYP3A inhibition) 
due to: grapefruit juice, allopurinol, calcium antagonists, 
amiodarone, antibiotics (macrolides, clarithromycin, 
josamycin, ponsinomycin, pristinamycin, doxycycline, 
gentamicin, tobramycin, ticarcillin, quinolones), keto-
conazole, oral contraceptives, methylprednisolone (high 
dosages), ranitidine, cimetidine 
 • Decrease in the cyclosporine level (CYP3A induction) 
due to: carbamazepine, phenytoin, barbiturates, met-
amizole, St. John’s wort 
 • Possible reinforcement of nephrotoxic adverse drug 
reactions by: aminoglycosides, amphotericin B, cipro-
floxacin, acyclovir, nonsteroidal antiphlogistics 
 • Specific interactions: 
 – Potassium-saving substances: increased risk of hyper-
potassemia 
 – Reduced clearance of: digoxin, colchicine, predniso-
lone, HMG-CoA reductase inhibitors (e.g. lovastatin), 
diclofenac 
 Absolute Contraindications  [25] 
 • Impaired renal function 
 • Insufficiently controlled arterial hypertension 
 • Severe infectious disease 
 Table 5.  Overview of important side effects of CsA [4, 30]
Frequency Side effects
Very frequent None
Frequent Renal failure (dose-dependent), danger of 
irreversible renal damage (long-term therapy), 
hypertension, gingival hyperplasia, reversible 
hepatogastric complaints (dose-dependent), 
tremor, weariness, headache, burning sensation 
in hands and feet, reversibly elevated blood 
lipids (especially in combination with 
corticosteroids), hypertrichosis
Occasional Seizures, gastrointestinal ulcerations, weight 
gain, hyperglycemia, hyperuricemia, 
hyperpotassemia, hypomagnesemia, acne, 
anemia
Rare Ischemic heart disease, pancreatitis, motor 
polyneuropathy, impaired vision, defective 
hearing, central ataxia, myopathy, erythema, 
itching, leukopenia, thrombocytopenia
Very rare Microangiopathic hemolytic anemia, hemolytic 
uremic syndrome, colitis (isolated cases), 
papillary edema (isolated cases), idiopathic 
intracranial hypertension (isolated cases)
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 • History of malignancy (possible exceptions: treated 
basal cell carcinoma, history of squamous carcinoma 
in situ) 
 • Current malignancy 
 • Simultaneous PUVA therapy 
 Relative Contraindications  [25] 
 • Previous potential carcinogenic therapies (e.g. arsenic, 
PUVA >1,000 J/cm 2 ) 
 • Psoriasis triggered by severe infection or drugs (β-
blockers, lithium, antimalarial drugs) 
 • Significant hepatic diseases 
 • Hyperuricemia 
 • Hyperkaliemia 
 • Simultaneous therapy with nephrotoxic drugs (see 
drug interactions) 
 • Simultaneous phototherapy (selective UV therapy, ex-
cept PUVA, see above) 
 • Simultaneous use of other systemic immunosuppres-
sive agents 
 • Simultaneous use of systemic retinoids or therapy with 
retinoids in the last 4 weeks prior to planned onset of 
therapy with cyclosporine 
 • Drug or alcohol-related diseases 
 • Long-term previous treatment with MTX 
 • Pregnancy/breast-feeding 
 • Vaccination with live vaccines 
 • Epilepsy 
 • Current treatment with castor oil preparations 
 In case of CsA overdosing, CsA should be stopped, 
drug levels for CsA should be measured; vital parameters, 
liver and kidney function as well as electrolytes should be 
measured.
 Limitation (FOPH) 
 None for psoriasis. It is however common practice to 
prescribe CsA for psoriasis without prior confirmation of 
coverage.
 Fumaric Acid Esters 
 FAEs in psoriasis have been known since 1959, but 
FAEs have so far been registered only in Germany in 
1995. Due to tolerability ( table 6 ), FAEs are slowly intro-
duced via Fumaderm initial ® (contains 30 mg dimeth-
ylfumarate) and Fumaderm ® (contains 120 mg dimeth-
ylfumarate); see  table  7 for a recommended dosage 
scheme.
 Up to 60% of patients suffer from transient gastroin-
testinal side effects in the first few weeks. In severe cases 
it is necessary to reduce the dosage and to discontinue 
treatment. The intake of FAEs with milk products can 
improve its gastrointestinal tolerability, as can a regular 
and stable time point during the day for drug intake. After 
increasing the dose up to Fumaderm ® 2–2–2 tablets and/
or a dose with a satisfactory psoriasis response, the main-
tenance dosage can be reduced based on individual treat-
ment requirements.
 FAEs have relatively few drug interactions (less than 
5%) and can be used also in comorbid patients on a case-
by-case basis  [30–32] . Prior to prescription, the reim-
bursement must be confirmed for every single patient by 
the respective health insurance  [3] .
 Contraindications  [33] 
 • Severe general disease 
 • Chronic gastrointestinal diseases 
 Table 6.  Overview of important side effects of FAEs [4]
Frequency Side effects
Very frequent Diarrhea, flush, mild leukopenia and 
lymphopenia (approx. 50% of patients)
Frequent Abdominal cramps, flatulence, severe 
lymphocytopenia (approx. 3% of patients), 
transient eosinophilia
Occasional Nausea, dizziness, headache, fatigue, 
proteinuria, increase in serum creatinine, 
increase in liver enzymes
Rare Allergic skin reaction
Very rare None
 Table 7.  Dosing scheme (tablets) for FAE therapy
 Fumaderm® initial Fumaderm®
Week 1 1 – 0–0  
Week 2 1 – 0–1  
Week 3 1 – 1–1  
Week 4  1 – 0–0
Week 5  1 – 0–1
Week 6  1 – 1–1
Week 7  2 – 1–1
Week 8  2 – 1–2
Week 9 and ongoing  2 – 2–2
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 • Severe liver and kidney diseases 
 • Chronic diseases accompanied by disturbances in leu-
kocyte counts and functions 
 • Malignancies 
 • Pregnant or lactating women 
 • Hypersensitivity to FAEs 
 Limitation (FOPH) 
 FAEs are off label in Switzerland and need to be im-
ported by an international pharmacy. It is obligatory to 
seek reimbursement of the health insurance provider pri-
or to prescribing FAEs.
 Methotrexate 
 MTX is indicated for moderate-to-severe psoriasis
and can also be efficacious in pustular or erythrodermic 
forms. MTX is also indicated in psoriatic arthritis. There 
is still no clear consensus about the use of folic acid dur-
ing MTX treatment. It could be shown that folic acid re-
duces the incidence of abnormal liver function tests and 
withdrawal from treatment as well as a trend towards a 
reduction in gastrointestinal side effects and stomatitis.
5 mg folic acid at least 24 h after MTX is commonly used, 
or it can also be taken 24 h before MTX in case of persist-
ing gastrointestinal side effects  [34, 35] ( table 8 ). Contra-
ception (women and men) is warranted during treatment 
and should be continued for 3 months after treatment 
discontinuation. More frequent laboratory tests are re-
quired in patients with an increased risk of elevated MTX 
levels (dehydration, diminished renal function) or when 
increasing the dosage.
 It is recommended to perform a chest X-ray before 
MTX initiation as a baseline image to compare against in 
case of signs of pneumonitis ( table 9 ). In up to 8% of the 
patients an MTX-induced pneumonitis occurs  [36] . The 
determination of procollagen III N-terminal peptide is 
controversial but recommended in the European and 
German S3 psoriasis guidelines and others  [4, 37–39] .
 Absolute Contraindications  [25] 
 • Severe infections 
 • Severe liver disease 
 • Renal failure 
 • Conception (men and women)/breast-feeding 
 • Alcohol abuse 
 • Bone marrow dysfunction/hematological changes 
 • Immunodeficiency 
 • Acute peptic ulcer 
 • Significantly reduced lung function 
 • Hypersensitivity to MTX 
 Relative Contraindications  [25] 
 • Kidney or liver disorders 
 • Ulcerative colitis 
 • History of hepatitis 
 • Lack of compliance 
 • Active desire to have a child for women of childbearing 
age and men 
 • Gastritis 
 • Diabetes mellitus 
 • Previous malignancies 
 • Congestive heart failure 
 Acute toxicity includes myelosuppression, mucosal 
(especially oral) ulceration and rarely cutaneous necrosis 
(especially if the dosage of MTX is increased too rapidly) 
 [34] . Calcium leucovorin serves as antidote to MTX-in-
duced hematological toxicity, but its efficacy decreases 
 Table 8.  Overview of important side effects of MTX [4, 30, 34]
Frequency Side effects
Very frequent Nausea, malaise, hair loss
Frequent Elevated transaminases, bone marrow suppres-
sion, gastrointestinal ulcers, pneumonitis
Occasional Fever, chills, depression, infections
Rare Nephrotoxicity, liver fibrosis and cirrhosis
Very rare Interstitial pneumonia, alveolitis
 Table 9.  Symptoms of MTX-induced pneumonitis
1 Acute onset of dyspnea
2 Fever >38° C
3 Tachypnea >28/min and dry cough
4 Radiological findings of interstitial or alveolar infiltrates
5 Leukocytosis ≤15,000 cells/mm3
6 Negative blood culture and expectorate cultures
7 Restrictive ventilation disorder in pulmonary function test 
and reduced CO2 diffusing capacity (<70%)
8 pO2 <7.5 kPa
9 Histology of bronchiolitis or interstitial pneumonitis with 
giant cells and lack of signs of infection
Diagnosis of MTX-induced pneumonitis is: 
Certain, if >6 of 9 criteria are positive
Probable, if >5 of 9 criteria are positive
Possible, if 4 of 9 criteria are positive
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with the delay after administration of MTX. In case of 
overdose, calcium leucovorin should be administered at 
20 mg (or 10 mg/m 2 ) i.v. or i.m. and repeated every 6 h 
intravenously, intramuscularly or orally (if given orally 
the dose of leucovorin should be increased by 15 mg). 
MTX levels should be measured every 12–24 h until the 
serum MTX concentration is below 10 –8 mol/l. If MTX 
levels are not available, continue giving leucovorin until 
the blood count has normalized and mucosal lesions have 
healed. To increase drug survival by inhibition of the de-
velopment of antidrug antibodies or enhancing efficacy, 
concomitant MTX is often added to TNF inhibitor treat-
ment, especially in patients receiving IFX  [40, 41] .
 Limitation (FOPH) 
 None for psoriasis. It is however common practice to 
prescribe MTX for psoriasis without prior confirmation 
of coverage.
 Adalimumab 
 ADA (Humira ® ) is a recombinant human IgG1 mono-
clonal antibody binding soluble and membrane-bound 
TNF-α  [42] and is indicated for moderate-to-severe pso-
riasis patients who failed a prior treatment with at least 
one conventional systemic drug or phototherapy. ADA is 
also indicated in psoriatic arthritis. The recommended 
dosage is 80 mg s.c. on day 0 for induction, followed by 
40 mg s.c. every other week beginning 1 week after induc-
tion for maintenance of treatment.
 In case of infection during treatment, stop temporar-
ily. In case of pregnancy, stop until the end of pregnancy 
and restart not earlier than 5 months after the last ADA 
injection, which counts also for breast-feeding. ADA 
should be discontinued 4–8 weeks prior to and may be 
restarted 2–3 weeks after a live attenuated vaccination 
 [34] . Patients should be informed about the potential risk 
for serious and atypical infections and in case of symp-
toms should seek medical advice. The material of the 
ADA syringe or pen is to be latex free ( table 10 ).
 Absolute Contraindications  [4] 
 • Concomitant immunosuppressive therapy 
 • Active chronic hepatitis B 
 • Active tuberculosis 
 • Congestive heart failure (NYHA grade III/IV) 
 • Pregnancy/breast-feeding 
 • Hypersensitivity to ADA 
 Relative Contraindications  [4] 
 • History of recurrent infections 
 • Underlying conditions predisposing to infections 
 • Psoriasis patients with concomitant systemic lupus er-
ythematosus or multiple sclerosis 
 • Live attenuated vaccines 
 • Localized infections 
 • Latent tuberculosis 
 • Patients living in geographical areas where tuberculo-
sis and histoplasmosis are widespread 
 • Hepatitis C 
 • >200 PUVA treatments (especially if followed by cy-
closporine use) 
 • Malignancies (apart from successfully treated non-
melanoma skin cancer and cervical dysplasia) and 
lymphoproliferative disorders 
 Limitation (FOPH) 
 Treatment of adults with severe plaque-type psoriasis 
who did not experience therapeutic success with UVB 
and PUVA or one of the following systemic therapies:
cyclosporine, MTX, acitretin. The treatment has to be 
stopped in case of no therapeutic success after 12 weeks. 
For psoriasis it can only be prescribed by dermatologists 
or dermatological university hospitals/outpatient clin-
ics.
 Etanercept 
 ETA (Enbrel ® ) is a soluble TNF receptor Fc fusion 
protein which binds soluble and membrane-bound 
TNF-α as well as lymphotoxin-β  [42] and is indicated for 
moderate-to-severe psoriasis patients who failed a prior 
treatment with at least one conventional systemic drug 
or phototherapy. ETA is also indicated in psoriatic ar-
 Table 10.  Overview of important side effects of ADA [30]
Frequency Side effect
Very frequent Injection site reaction
Frequent Upper respiratory tract infections, sinusitis,
headache, rash
Occasional Tuberculosis, reactivation of latent tuberculosis, 
TNF-α-induced lupus-like syndrome, paradoxi-
cal psoriasis
Rare Lymphoma
Very rare None
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thritis. The recommended initial dosage is 1 × 50 mg or 
2 × 50 mg weekly over 12 weeks followed by a mainte-
nance dosage of 1 × 50 mg weekly. 2 × 50 mg for the in-
duction phase has a faster onset compared to 1 × 50 mg 
 [43] .
 In case of infection during treatment, stop temporar-
ily, and in case of pregnancy, stop until the end of preg-
nancy and breast-feeding. ETA can be discontinued with-
out any relevant loss of efficacy at re-initiation as no neu-
tralizing antibodies against ETA are produced  [44] . ETA 
should be discontinued 4–8 weeks prior to and may be 
restarted 2–3 weeks after a live attenuated vaccination. 
Patients should be informed about the potential risk for 
serious and atypical infections and in case of symptoms 
should seek medical advice. The removable cap of the
SureClick ® autoinjector and the prefilled syringe contain 
latex which may cause an allergic reaction in latex-sensi-
tive individuals ( table 11 ).
 Absolute Contraindications  [4] 
 • Active (chronic) infections (including tuberculosis 
and active chronic hepatitis B) 
 • Congestive heart failure (NYHA grade III or IV) 
 • Hypersensitivity to ETA 
 Relative Contraindications  [4] 
 • Pregnancy/breast-feeding 
 • >200 PUVA treatments (especially if followed by cy-
closporine use) 
 • HIV or AIDS 
 • Hepatitis C and B 
 • Congestive heart failure (NYHA grade I or II) 
 • Demyelinating disease (also family history) 
 • Malignancies (apart from successfully treated non-
melanoma skin cancer and cervical dysplasia) or lym-
phoproliferative disorders 
 • Live attenuated vaccines 
 Limitation (FOPH) 
 Treatment of adults with severe plaque-type psoriasis 
who did not experience therapeutic success with UVB 
and PUVA or one of the following systemic therapies: 
cyclosporine, MTX, acitretin. The treatment has to be 
stopped in case of no therapeutic success after 12 weeks. 
For psoriasis it can only be prescribed by dermatologists 
or dermatological university hospitals/outpatient clin-
ics. Cost coverage has to be granted by the patient’s 
health insurance.
 Infliximab 
 IFX (Remicade ® ) is a chimeric (mouse/human) mono-
clonal antibody binding soluble and membrane bound 
TNF-α  [42] and is indicated for moderate-to-severe pso-
riasis patients who failed a prior treatment with at least 
one conventional systemic drug or phototherapy and at 
least one TNF-α antagonist treatment. IFX is also indi-
cated in psoriatic arthritis. IFX is the only available intra-
venous biological for psoriasis and is available as powder 
in 100-mg vials which should be stored at 2–8  °  C and re-
constituted in 10 ml sterile water. The total dosage should 
be diluted with 250 ml of 0.9% saline solution, infused 
over a period of 2 h and monitored 1 h after treatment. 
The recommended dosage is 5 mg/kg body weight at 
weeks 0, 2 and 6 for induction followed by infusions every 
8 weeks.
 In rheumatological conditions, IFX is often combined 
with MTX to improve long-term efficacy. It could addi-
tionally be shown that the treatment survival rates of all 
three TNF-α antagonists are better in combination with 
MTX  [40, 45] . In case of overdose, the patient should be 
followed closely for adverse events, particularly infections 
( table 12 ).
 Table 11.  Overview of important side effects of ETA [30]
Frequency Side effect
Very frequent Injection site reactions, infections (upper 
respiratory tract, bronchitis, skin)
Frequent Pruritus, fever, allergic reactions
Occasional Serious infection, urticaria, angioedema, 
thrombocytopenia, nonmelanoma skin cancers, 
uveitis, interstitial lung disease, vasculitis, 
psoriasis (including new onset or worsening and 
pustular)
Rare Opportunistic infections, tuberculosis, Stevens-
Johnson syndrome, erythema multiforme, 
pancytopenia, anemia, leukopenia, neutropenia, 
serious allergic reactions/anaphylactic reactions, 
elevated liver enzymes, autoimmune hepatitis, 
CNS-demyelinating events (e.g. multiple 
sclerosis), localized demyelinating events (e.g. 
optic neuritis, transverse myelitis), seizures, 
worsening of congestive heart failure, cutaneous 
vasculitis, cutaneous lupus, lupus-like syndrome, 
lymphoma, melanoma
Very rare Toxic epidermal necrolysis, demyelinating 
polyneuropathy including Guillain-Barré 
syndrome, aplastic anemia
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 Managing of Side Effects 
 Infusion reactions occur in about 20% of patients with 
an increased risk in patients who developed antibodies 
against IFX. Most reactions are mild to moderate (flush, 
pruritus, chills, headache, urticaria), and about 1% are
severe (anaphylactic reactions, serum-sickness-like de-
layed-type hypersensitivity reactions like myalgia, ar-
thralgia and/or exanthema occurring between 1 and 14 
days after infusion). In case of mild-to-moderate reac-
tions, treatment can be continued with the following 
measures: the infusion rate should be decreased or tem-
porarily stopped, and pretreatment with oral antihista-
mines, paracetamol and/or corticosteroids 1 day before 
and directly before the next infusion should be performed 
 [30, 46, 47] .
 Up to 8% of patients develop elevated liver enzymes 
(aspartate/alanine transaminases >150 U/l and more than 
twice from baseline). With close monitoring, treatment 
can be continued in most cases (possible if values <3 times 
the upper limit of normal; with caution if values are 3–5 
times the upper limit of normal; stop if values are >5 times 
the upper limit of normal).
 More than 50% of patients develop anti-nuclear anti-
bodies and about 17% anti-dsDNA antibodies. In case of 
a lupus-like syndrome (45% cutaneous, 55% systemic) 
where also other autoantibodies occur, treatment should 
be discontinued as soon as the diagnosis is made, which 
leads to a resolution in 94% of cases after 3 weeks to 6 
months  [48, 49] .
 In severe disease with pulmonary, renal, neurological 
disease, an additional initiation of corticosteroids and/or 
immunosuppression might be necessary. Rechallenging 
with another TNF inhibitor might be a potential option 
 [50–53] .
 In case of infection during treatment, interrupt IFX 
temporarily. In case of pregnancy, IFX should normally be 
stopped until the end of pregnancy. In women of child-
bearing age, reliable contraception is required until 6 
months after the last infusion. IFX should be discontinued 
4–8 weeks prior to and may be restarted 2–3 weeks after a 
live attenuated vaccination. Patients should be informed 
about the potential risk for serious and atypical infections 
and in case of symptoms should seek medical advice.
 Absolute Contraindications 
 • Active tuberculosis 
 • Significant active infection 
 • Active chronic hepatitis B 
 • Heart failure (NYHA grade III/IV) 
 • Hypersensitivity to IFX, murine proteins or any com-
ponent of the formulation 
 • Pregnancy or breast-feeding 
 Relative Contraindications 
 • Demyelinating diseases 
 • Live attenuated vaccines 
 • >200 PUVA treatments (especially if followed by cy-
closporine use) 
 • Malignancies (apart from successfully treated non-
melanoma skin cancer and cervical dysplasia) or lym-
phoproliferative disorders 
 • Hepatobiliary disorders 
 • Hepatitis C 
 Limitation (FOPH) 
 Treatment of adults with severe plaque-type psoriasis 
where UVB and PUVA or one of the systemic therapies 
(cyclosporine, MTX, acitretin) and a TNF-α blocker (e.g. 
ETA) showed no therapeutic success. The treatment has 
to be stopped in case of lacking therapeutic success after 
14 weeks. The maximum duration of treatment is 1 year. 
In case of psoriasis it can only be prescribed by derma-
tologists or dermatological university hospitals/outpa-
tient clinics. Cost coverage has to be granted by the pa-
tient’s health insurance.
 Secukinumab 
 SEC (Cosentyx ® ) is a fully human monoclonal IgG1 
antibody that binds and antagonizes the cytokine IL-17A. 
It can be prescribed to patients with moderate-to-severe 
 Table 12.  Overview of important side effects of IFX [30]
Frequency Side effect
Very frequent Infusion reactions, headache, viral infections 
(influenza, herpes virus infections)
Frequent Bacterial infections (sepsis, cellulitis), flush, 
pruritus, urticaria, hypotension, hypertension, 
fever, transaminase elevation, dizziness
Occasional Serum-sickness-like disease, (cutaneous) lupus 
erythematosus syndrome, heart failure, severe 
infections, tuberculosis, anaphylactoid reaction
Rare Opportunistic infections, pancytopenia, 
vasculitis, melanoma, leukemia, lymphoma, 
non-Hodgkin lymphoma, demyelinating 
diseases
Very rare None
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psoriasis who failed UVB and PUVA or one of the follow-
ing systemic therapies: CsA, MTX, acitretin. 
 The recommended dosage is 300 mg s.c. at week 0, 1, 
2 and 3 for induction, followed by 300 mg s.c. every
4 weeks for maintenance of treatment starting in week 4 
 [54] .
 In case of infection during treatment, interrupt tem-
porarily, and in case of pregnancy, stop until the end of 
pregnancy and breast-feeding. Patients should be in-
formed about the potential risk for serious and atypical 
infections and in case of symptoms should seek medical 
advice  [55] .
 The removable cap of the Cosentyx SensoReady ® pen 
and the Cosentyx prefilled syringe contain natural rubber 
latex, which may cause an allergic reaction in latex-sensi-
tive individuals ( table 13 ).
 Absolute Contraindications 
 • Active tuberculosis or acute, severe infections 
 • Live attenuated vaccines  
 • Active chronic hepatitis B 
 • Pregnancy/breast-feeding 
 • Hypersensitivity to secukinumab 
 Relative Contraindications 
 • Crohn’s disease (monitor closely) 
 • Malignancies (apart from successfully treated non-
melanoma skin cancer and cervical dysplasia) and lym-
phoproliferative disorders 
 With lack of data or recommendations, the following 
medical states should be considered very carefully: latent 
tuberculosis, hepatitis C and HIV.
 Limitation (FOPH) 
 Treatment of adults with severe plaque-type psoriasis 
who did not experience therapeutic success with UVB and 
PUVA or one of the following systemic therapies:
cyclosporine, MTX, acitretin. The treatment has to be 
stopped in case of no therapeutic success after 12 weeks. For 
psoriasis it can only be prescribed by dermatologists or der-
matological university hospitals/outpatient clinics. Cost 
coverage has to be granted by the patient’s health insurance. 
 Ustekinumab 
 UST (Stelara ® ) is a recombinant, fully human IgG1κ 
antibody with high specificity and affinity to the p40 sub-
unit of IL-12 and IL-23. It can be prescribed to patients 
with moderate-to-severe psoriasis who failed a prior treat-
ment with at least one conventional systemic drug or pho-
totherapy. UST is also registered for psoriatic arthritis.
 The recommended dosage is 45/90 mg s.c. at weeks 0 
and 4 for induction, followed by 45/90 mg s.c. every 12 
weeks for maintenance of treatment (i.e. 45 mg in patients 
<100 kg body weight, 90 mg in patients  ≥ 100 mg body 
weight). As the price of the 45- and 90-mg doses is the 
same now in Switzerland, dose adjustment of patients re-
ceiving 45 mg with insufficient response to 90 mg every 
12 weeks may be beneficial  [56] .
 In case of infection during treatment, stop temporarily, 
and in case of pregnancy, stop until the end of pregnancy. 
UST should be discontinued 15 weeks prior to live attenu-
ated vaccination or pregnancy. It may be restarted 2 weeks 
after live attenuated vaccination. Patients should be in-
formed about the potential risk for serious and atypical infec-
tions and in case of symptoms should seek medical advice.
 The removable cap of the prefilled syringe contains la-
tex which may cause an allergic reaction in latex-sensitive 
individuals ( table 14 ).
 Absolute Contraindications  [4] 
 • Hypersensitivity to the active substance or to any of 
the excipients 
 • Clinically important active infection including un-
treated latent tuberculosis 
 Relative Contraindications  [4] 
 • Malignancies (apart from successfully treated non-
melanoma skin cancer and cervical dysplasia) and 
lymphoproliferative disorders 
 • Pregnancy 
 • Live vaccines 
 Table 13.  Overview of important side effects of secukinumab [30]
Frequency Side effect
Very frequent Nasopharyngitis
Frequent Upper respiratory tract infections, rhinitis, 
pharyngitis, rhinorrhea, oral herpes, 
diarrhea, urticaria
Occasional Neutropenia, oral candidosis, tinea pedis, 
esophageal candidosis, conjunctivitis, 
elevated transaminases, elevated bilirubin
Rare None
Very rare None
Frequency not 
reported (causal 
connection unclear)
Exacerbation of Crohn’s disease, 
anaphylaxis, staphylococcal skin infections
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 Limitation (FOPH) 
 Treatment of adults with severe plaque-type pso-
riasis who did not experience therapeutic success with 
UVB and PUVA or one of the following systemic ther-
apies: cyclosporine, MTX, acitretin. The treatment has 
to be stopped in case of lacking therapeutic success after 
3 injections. For psoriasis it can only be prescribed by 
dermatologists or dermatological university hospitals/
outpatient clinics. Cost coverage has to be granted by 
the patient’s health insurance.
 Treatment Goals and Transitioning between 
Systemic Drugs 
 Goals for Short-Term Efficacy 
 Before the decision for a systemic therapy of any kind 
is made, the expectations of both patient and physician 
should be considered, as this is crucial for the choice of 
treatment and adherence. This conversation should cover 
e.g. efficacy, side-effects, preference of oral versus inject-
able drugs, monitoring, comorbidities and costs.  Tables 1 
and  2 show the widely variable PASI75 and PASI90 re-
sponses after 10–24 weeks  [20, 24, 57, 58] . Where head-
to-head studies are lacking, direct comparison between 
drugs is not advisable.
 In case where moderately efficacious drugs yield sig-
nificant additional advantages such as oral intake, few 
side effects and/or potentially cheap long-term therapy, 
the achievement of PASI75 or PASI90 within 3 months 
might play a secondary role. For newer, expensive drugs 
such as all the biologicals and novel small molecules, a 
high efficacy should be expected and taken into account 
when evaluating the treatment response. A recent Euro-
pean consensus  [59] goal (modified by adding the Pre-
cisePASI) is useful and is utilized regularly in the tertiary 
centers in Switzerland. The aim of effective treatment 
( fig. 1 ) is a PASI reduction from baseline to time of evalu-
ation (ΔPASI) as well as a reduction of the DLQI. If after 
an induction phase of up to 16 weeks (depending on med-
ication) these end points are met, the medication can be 
continued. If the PASI value is not improved by at least 
50%, or if the DLQI is still more than 5 points and the 
PASI response is between 50 and 75%, the treatment reg-
imen is not satisfactory and needs to be modified. If the 
DLQI is below 5 points, the treatment regimen could be 
continued even if the PASI response is between 50 and 
75%  [17] . In the future, those thresholds might even be 
increased (online suppl. fig.  1) to PASI90 and Precise 
PASI90 and DLQI <5 as main goals of treatment  [24, 57, 
60] . As quality of life is an important goal in the treat-
ment, and adherence should also be considered in defin-
ing a severe psoriasis in patients not having reached PASI 
of 10, we recommend that patients fill out the DLQI (Ap-
pendix 1) prior to consultation  [61–63] . Different lan-
guage versions of the DLQI (for English, German, French 
and Italian see the online suppl. material) can be found 
online: http://sites.cardiff.ac.uk/dermatology/quality-of-
life/dermatology-quality-of-life-index-dlqi/dlqi-differ-
ent-language-versions/.
©3UHFLVH3$6,
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'/4,!
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Modify
treatment
regimen
Continue
treatment
regimen
 Fig. 1. Current treatment goals, adapted from [59], modified by 
adding the PrecisePASI. 
 Table 14.  Overview of important side effects of UST [30]
Frequency Side effect
Very frequent None
Frequent Upper respiratory tract infections, 
nasopharyngitis, erythema and pain at injection 
site, pruritus, dental infections, dizziness, 
headache, sore throat, diarrhea, myalgia, 
arthralgia, fatigue, nausea, vomiting
Occasional Herpes zoster, viral upper respiratory tract 
infections, cellulitis, pustular psoriasis, injection 
site reactions (swelling, pruritus, induration, 
bleeding, hematoma), depression, facial palsy, 
allergic reactions including rash and urticaria, 
rhinitis, exfoliative dermatitis
Rare Severe allergic reactions including anaphylaxis 
and angioedema, exfoliative dermatitis 
(erythroderma)
Very rare None
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 Goals for Long-Term Efficacy 
 For 52 weeks every 3 months and thereafter every 6 
months, the same evaluation should be performed and 
the treatment strategy reevaluated. A potential future 
goal of reaching PASI90 within 52 weeks after starting 
therapy seems achievable with newer therapies. However, 
all options should be considered and discussed with the 
patient, including keeping alternative drug options avail-
able in case a switch should be required later on.
 Drug Transitioning 
 Optimizations of small molecule therapies include the 
combination of the best effective dose and the lowest rate 
of possible side effects (see each systemic medication) 
suggested by the progressive psoriasis initiative as an ev-
idence-based consensus on treatment optimization and 
transitioning [64].
 Transitioning from small molecules (MTX, CsA, 
acitretin) therapy to biological therapy can in most cases 
be performed without a washout period or even overlap-
ping if no safety issues arise. APR was not discussed in this 
work. Combining conventional systemic therapy with bi-
ological therapy is currently considered off-label treat-
ment. Nevertheless, this strategy is often used to improve 
efficacy, optimize the risk-benefit profile, reduce the risk 
of immunogenicity (with MTX)  [41] and improve long-
term disease management. Monitoring should be the 
same as for monotherapy with intervals defined by the 
agent with more stringent monitoring criteria. If syner-
gistic toxicity is suspected, more frequent monitoring in-
tervals may be required and additional monitoring pa-
rameters added. Switching between biologicals due to 
failure is recommended without a washout period at the 
time of the next scheduled dose. In case of switching from 
UST to another biological, the new drug can be used as 
early as 2–4 weeks after the last dose of UST.
 Temporary Treatment Interruptions 
 Long-term disease control is achieved with a continu-
ous therapy adjusted to the pathogenesis, comfortable 
drug intake, long-term safety with minimal pharmaceuti-
cal interactions and minimal monitoring. Temporary in-
terruption of systemic therapy can be considered with 
careful follow-up (please note: in CsA therapy, careful 
dose reduction is indicated due to the risk of rebound of 
disease). Recurrence can be expected within 2–6 months. 
Before interrupting or stopping a certain therapy, all rel-
evant factors should be considered, name ly comorbidi-
ties including the presence of psoriatic arthritis, individ-
ual risk factors, long-term safety, prior course of disease, 
especially the pattern of flares and rebounds, availability 
of other treatment options in case of rebound (and/or 
lower response after treatment reinitiation) and patients’ 
preference. Recurrence of limited disease may be con-
trolled with topical therapy, systemic therapy should be 
reintroduced if the Physician’s Global Assessment ap-
pears to be >2 and/or PASI  ≥ 5 and/or DLQI  ≥ 5 or in case 
of rapid recurrence.
 Adjusting Dose and Intervals of Biological Therapy 
 Dose reduction during successful biological mono-
therapy can be considered, but there is a risk of loss of 
efficacy due to immunogenicity by neutralizing anti-
drug antibody formation  [44] , especially in case of in-
fliximab and adalimumab. Dosing intervals have been 
lengthened with ADA and ETA, but this is not recom-
mended for IFX and UST. Dose reduction is possible for 
IFX down to a minimum of 3 mg/kg body weight, for 
UST in patients who are treated with 90 mg s.c. every 12 
weeks and for ETA in patients who are treated with 50 
mg s.c. every week or 25 mg s.c. biweekly. Strategies for 
nonresponders are to increase the dosage for ADA (40 
mg every other week to 40 mg every week), for ETA (50 
mg every week to 50 mg biweekly), for UST (45 mg every 
12 weeks to 90 mg every 12 weeks  [56] , with the possibil-
ity to further decrease the intervals to every 8 weeks 
 [65] ) and for IFX (interval reduction from every 8 weeks 
to every 6 weeks and in special cases an increase in dose 
>5 mg/kg body weight). These strategies can increase 
costs of treatment enormously, therefore secondary loss 
of response due to immunogenicity has to be ruled out 
 [66] . Combination of small molecules with biologicals is 
discussed above.
 Comorbidity Screening 
 In recent years comorbidities of psoriasis like psori-
atic arthritis, cardiovascular disease and risk factors in-
cluding obesity, arterial hypertension, dyslipidemia and 
type 2 diabetes mellitus, nonalcoholic fatty liver disease, 
inflammatory bowel disease, lymphoma and skin cancer, 
anxiety and depression, tobacco and alcohol consump-
tion have attracted particular interest.
 To prevent progression and treat psoriasis-associated 
comorbidities as early as possible, an integrated manage-
ment is required that also takes the side effects of system-
ic treatments for psoriasis such as arterial hypertension 
or hyperlipidemia into account. Additionally, medication 
which can worsen psoriasis like β-blockers, angiotensin-
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converting enzyme inhibitors, antimalarials, lithium, in-
terferons, and less commonly contraceptives or nonste-
roidal antirheumatic drugs should be ruled out, especial-
ly in newly arising forms of psoriasis. Lastly, uncontrolled 
interruption of systemic corticosteroid treatment should 
be considered as a risk factor for flares of psoriasis. Six-
monthly screening intervals for comorbidities have been 
suggested in patients with systemic treatment and every 
12 months in patients receiving topical treatment (non-
interfering with the recommended control intervals dur-
ing different treatments)  [67] ( table 15 ).
 Psoriatic arthritis is a common comorbidity in psoria-
sis patients (up to 41%) and supposed to be underdiag-
nosed  [68] . We recommend the use of a fast and simple 
screening tool for psoriatic arthritis, e.g. the PEST assess-
ment (Psoriasis Epidemiology Screening Tool) which the 
patients can fill out prior to consultation (Appendix 2; see 
also online suppl. material for different language ver-
sions) or at least to routinely ask for joint and back pain 
 [69, 70] .
 End Notes 
 Guidelines are intended for use by clinicians, derma-
tologists in private practice and other specialists involved 
in the treatment of patients with psoriasis vulgaris and also 
provide a guide for health insurers and policy-makers.
 The description of selected therapies ( tables 16 ,  17 ) is 
intentionally restricted to the most relevant aspects in the 
opinion of the guidelines’ expert committee. Certain as-
pects which are not listed separately but might be of inter-
est are assumed to be a part of the physician’s duty of care.
 Physicians are advised to carefully read the package 
insert and manufacturer information and to determine 
whether dosage recommendations and other information 
contained in the guidelines, such as contraindications 
and drug interactions, are complete and current. Correct 
dosage and administration are solely the responsibility of 
the administering physician.
 Science and medical research are under constant de-
velopment, and our knowledge is constantly growing. In 
case of any inaccuracies we kindly ask the readers of this 
guideline to inform us. We took great care to ensure that 
this guideline represents current knowledge  [3] .
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 Table 15.  Laboratory screening for comorbidities
Complete blood count
Liver enzymes: alanine transaminase, aspartate transaminase,
γ-glutamyltransferase, alcaline phosphatase
Renal function: creatinine, estimated glomerular filtration rate
Weight, height, and waist circumference
Blood pressure
Hemoglobin A1c, fasting blood glucose
Lipids: total cholesterol, low-density lipoprotein (LDL),
high-density lipoprotein (HDL), triglycerides
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 Table 16.  Small molecules
Methotrexate Acitretin Fumaric acid esters Cyclosporine A Apremilast
Mode of action Folate analog acts as 
immunosuppressive by 
inhibiting the dihydrofolate 
reductase and leading to 
inhibition of DNA 
synthesis
Antiproliferative effect on 
keratinocytes by binding to 
nuclear RAR and RXR 
receptor
Anti-inflammatory and 
cytoprotective via e.g. Nrf2 
induction, NF-κB inhibition, 
action on immune/glial and 
endothelial cells and 
keratinocytes
Immunosuppressive via 
inhibition of calcineurin/
NFAT pathway and JNK 
signaling, esp. in T cells
Phosphodiesterase-4 inhibition 
results in cAMP increase in 
immune and nonimmune cells, 
leading to decreased expression 
of inducible NOS, TNF-α, IL-23 
and increased IL-10
Registration
in dermatology 
[30]
Severe psoriasis 
unresponsive to 
phototherapy or acitretin
Severe pustular and plaque 
psoriasis
Moderate-to-severe plaque 
psoriasis unresponsive to 
topicals [71] (Germany only)
Severe psoriasis unresponsive 
to other therapies
Moderate-to-severe plaque 
psoriasis which failed MTX, 
CsA, acitretin or PUVA
Prior treatment 
initiation [5, 72]
Full blood count, 
transaminases, creatinine, 
urine analysis, β-HCG, 
CRP, HBs-Ag, HBs-Ab, 
HBc-Ab, HCV screening, 
HIV, chest X-ray
Blood count, transaminases, 
creatinine, fasting blood 
lipids, fasting glucose, 
β-HCG (once monthly up to 
2 – 3 years after stop of 
therapy)
Blood count, transaminases, 
creatinine, β-HCG, urine 
analysis
Blood count, transaminases, 
creatinine, electrolytes incl. 
Mg, K, urine analysis, lipids, 
uric acid, HBs-Ag, HBs-Ab, 
HBc-Ab, HCV screening, HIV, 
blood pressure at two different 
time points, β-HCG
Screening for HBs-Ag, HBs-Ab, 
HBc-Ab, HCV and HIV; 
creatinine, β-HCG
Optional: blood count, 
transaminases, CRP, IFN-γ 
release test (tuberculosis)
Laboratory 
values, control 
intervals [5]
Differential blood count, 
creatinine, liver values, 
CRP after 1, 2, 3, 4, 5, and 
12 weeks, then every
3 months; fibroscan every 
1.5 g of cumulative dose of 
MTX [64]
Blood count every 8 weeks, 
liver values after 4, 8, then 
every 8 weeks, pregnancy test 
1 × monthly, lipids after 4, 
then every 12 weeks
Blood count, liver/kidney 
values, urine analysis monthly 
until month 4, then every
8 weeks
Blood count, transaminases, 
electrolytes (Mg, K), creatinine, 
urine at weeks 2, 4, then every 
4 weeks; uric acid every
4 weeks, lipids every 4 weeks; 
blood pressure after 2, 4, 6, 8, 
10, and 12 weeks, then every 
month
Optional: blood count, CRP, 
AST/ALT, creatinine
Administration p.o. and s.c. p.o. p.o. p.o. p.o.
Dosage [5] Induction with 7.5 – 15 mg/
week, maintenance up to
25 mg/week as needed;
24 – 48 h after application 5 
mg folic acid orally, in case 
of ongoing gastrointestinal 
complaints also 24 h before 
MTX
Induction with 0.3 – 0.5 mg/
kg/day for 4 weeks, then
0.5 – 0.8 mg/kg/day
Induction with 1 tablet 
Fumaderm® initial (30 mg) 
daily and increase weekly with 
1 tablet until 1 – 1–1 for
1 week, switch to 1 tablet 
Fumaderm® (120 mg) daily 
and increase weekly with
1 tablet up to 2 – 2–2 (see
table 7)
Induction with 2.5 – 3 mg/kg/
day, in case of inefficiency 
increase dosage with 0.5 – 
1 mg/kg/day up to a maximum 
of 5 mg/kg/day; interval 
therapy (8 – 16 weeks) with a 
dosage reduction at the end of 
induction therapy (e.g. 0.5 mg/
kg body weight every 14 days) 
or continuous long-term 
therapy with dosage reduction, 
e.g. 50 mg every 4 weeks after 
week 12
Induction over 5 days
Day 1: 10 – 0–0 mg
Day 2: 10 – 0–10 mg
Day 3: 10 – 0–20 mg
Day 4: 20 – 0–20 mg
Day 5: 20 – 0–30 mg
Day 6 and ongoing/
maintenance: 30 mg twice daily
Median onset
of effect [5]
4 – 6 weeks 4 – 8 weeks 6 weeks 4 weeks 10 weeks
PASI75 [5] Week 16: 35 – 75% [73 – 75] Week 12: 25 – 41% 
(monotherapy) [76, 77], 94% 
(re-PUVA) [78]
Week 16: 50 – 70% [31] Weeks 8 – 16: 50 – 70%, dose-
dependent, 3 mg/kg [79, 80]
Week 16: 32 – 41% [81]
PASI90 Week 10: 19%
Week 22: 39% [82]
Up to 40% [83] (time point 
unclear)
Week 16: 9% [84] Week 4: at least 40% [85, 86] Week 16: 9.8% [81]
Contra-
indications [5]
Absolute: severe infections, 
severe liver disease, renal 
failure, conception (men 
and women)/breast-
feeding, alcohol abuse, 
bone marrow dysfunction/
hematological changes, 
immunodeficiency, acute 
peptic ulcer, significantly 
reduced lung function, 
hypersensitivity to MTX
Relative: kidney or liver 
disorders, ulcerative colitis, 
history of hepatitis, lack of 
compliance, active desire to 
have a child for women of 
childbearing age and men, 
gastritis, diabetes mellitus, 
previous malignancies, 
congestive heart failure
Caution in case of: lung 
diseases, live vaccination, 
multiple drug consumption
Absolute: severe renal or 
hepatic dysfunction, 
hepatitis, women of 
childbearing age (see chapter 
acitretin), excessive alcohol 
consumption, incompatible 
comedication, unwillingness 
to cease blood donation 
during and until 1 year after 
treatment, hypersensitivity 
to acitretin
Relative: alcohol abuse, 
diabetes mellitus, contact 
lenses, childhood, history of 
pancreatitis, hyperlipidemia 
(particularly 
hypertriglyceridemia) and 
drug-controlled 
hyperlipidemia, 
atherosclerosis
Caution in case of: 
tetracyclines because of the 
risk of pseudotumor cerebri; 
relative contraindication for 
MTX
Severe general disease, chronic 
gastrointestinal diseases, 
severe liver and kidney 
diseases, chronic diseases 
accompanied by disturbances 
in leukocyte counts and 
functions, malignancies, 
pregnant or lactating women, 
hypersensitivity to FAEs
Caution in case of: 
concomitant use of MTX, 
retinoids, CsA, psoralen, 
nephrotoxic medication
Absolute: kidney dysfunction, 
uncontrolled arterial 
hypertension, uncontrolled 
infection, current or past 
malignancy (exception 
nonmelanoma skin cancer), 
hypersensitivity to CsA; 
relative: liver dysfunction, 
pregnancy and lactation, 
concomitant use of substances 
that interact with CsA, 
simultaneous phototherapy or 
PUVA pretherapy with a 
cumulative dose >1,000 J/cm2, 
concomitant use of other 
immunosuppressants, 
retinoids, or long-term 
pretherapy with MTX, 
uncontrolled chronic hepatitis 
B (positive HbsAg)
Absolute: rare hereditary 
problems of galactose 
intolerance, lapp lactase 
deficiency or glucose-galactose 
malabsorption, pregnancy/
breast-feeding, hypersensitivity 
to apremilast, live vaccines
Relative: severe renal 
impairment (creatinine 
clearance <30 ml/min estimated 
by the Cockcroft-Gault 
equation), dose should be 
reduced to 30 mg once daily, 
caution in case of depression, 
underweight at the start of 
treatment
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 Table 17.  Biological therapies
 Anti-TNF-α Anti-p40 (IL-12/23) Anti-IL-17A
E nbrel® Remicade® Humira® Stelara® Cosentyx®
Generic name Etanercept ETA Infliximab IFX Adalimumab ADA Ustekinumab UST Secukinumab SEC
Producer Pfizer Centocor/MSD AbbVie AG Janssen Novartis
Mode of action Human TNF receptor Fc 
fusion protein which binds 
soluble/membrane-bound 
TNF-α and lymphotoxin-β
Chimeric monoclonal IgG1, 
binds soluble and 
membrane-bound TNF-α
Human monoclonal IgG1 
antibody, binds soluble and 
membrane-bound TNF-α
Human monoclonal IgG1 
antibody, binds and blocks 
p40 of IL-12 und IL-23 [90]
Fully human monoclonal 
IgG1 antibody, binds and 
blocks IL-17A
Registration in 
dermatology [30]
Plaque-type psoriasis in adults, in case of ETA, IFX, ADA, and UST also psoriatic arthritis, in case of ETA indicated from the age of 6 years
Swiss health 
insurance coverage
Yes (IFX: in case of failure of previous TNF inhibitor treatment)
Limitation for 
reimbursement [17]
PASI >10 or BSA >10% and/or DLQI >10 and unsatisfactory response to phototherapy or 1 prior systemic treatment (like CsA, MTX, acitretin); in case of IFX 
also failure to one other TNF blocker in label for psoriasis; see each medication for detailed information
Galenic form Prefilled syringe, pen Lyophilisate Prefilled syringe, pen Prefilled syringe Prefilled syringe, pen
Prior treatment 
initiation
Full blood count, liver enzymes, creatinine, urine analysis, urine pregnancy test, CRP/ESR; optional: ANA; screening for HBV, HCV, HIV, and tuberculosis, 
incl. chest X-ray
Laboratory 
values [81]
Full blood count, CRP, liver transaminases, creatinine, urine analysis, β-HCG
Control 
intervals
Months 1, 3, then every
3 months
Before every infusion Months 1, 3, then every
3 months
Before each injection Months 1, 3, then every 
3 months
Administration s.c. i.v. s.c. s.c. s.c.
Dosage 1 × 50 mg/week or 2 × 25 mg/
week [91]; alternative 2 ×
50 mg/week for 12 weeks;
0.8 mg/kg/week in children
5 mg/kg in weeks 0, 2, 6, 
then every 8 weeks; 
combination with MTX can 
prolong drug survival [41]
80 mg in week 0, 40 mg in 
week 1, then every 2 weeks 
40 mg
Weeks 0 and 4, followed 
every 12 weeks: 45 mg s.c. 
<100 kg, 90 mg s.c. ≥100 kg
300 mg in weeks 0, 1, 2, 3, 
followed every 4 weeks, 
starting in week 4
Methotrexate Acitretin Fumaric acid esters Cyclosporine A Apremilast
Selected side 
effects and
action [5]
Dose reduction in case of 
stomatitis, nausea, 
epigastric pain, depression, 
diarrhea, hair loss; 
interrupt therapy in case of 
gastrointestinal bleeding, 
infections, elevated liver 
enzymes; stop therapy in 
case of pneumonitis; 
leucovorin in case of 
overdose
Emollients, artificial tears,
no contact lenses in case of 
hypervitaminosis A, cheilitis, 
conjunctivitis; stop in case of 
effluvium; diet and lipid-
lowering agents in case of 
hyperlipidemia
Intake with milk in case of 
gastrointestinal complaints; 
dose reduction in case of 
leukocyte counts below 3,000/
μl, lymphocyte counts below 
500/μl, increase in serum 
creatinine over 30% of baseline 
value, proteinuria, persisting 
eosinophilia of 25% increase; 
stop if dose reduction does not 
lead to normalization of these 
parameters
Increase fluid intake, reduce 
dose in case of creatinine 
increase of ≥30%; dental 
hygiene or stop in case of 
gingival hyperplasia; ≥200 mg/
day in case of hypomagnese-
mia; reduce CsA by 25% and
2 – 3 liters of fluids/day in case 
of hyperpotassemia; reduce 
CsA by 25% when 
transaminases are 2 × above 
the upper limit
Diarrhea (usually transient, use 
symtomatic therapy if persisting 
infection has to be ruled out), 
nausea, urinary tract infection, 
bronchitis, upper respiratory tract 
infections, nasopharyngitis, lack of 
appetite, insomnia, migraine, 
headache, cough, vomiting, 
dyspepsia, frequent defecation, 
epigastralgia, back pain, fatigue, 
hypersensitivity, exanthema, 
weight loss
Cost per year, 
CHF
Up to 2,100 (15 mg/week 
excluding folic acid 
supplements) [30]
1,267 (35 mg/day) [30] 7,196 (6 tablets/day) 3,487 (200 mg/day, 3 mg/kg in 
a 66-kg person) [30]
13,702.75 (incl. starter pack)
Therapy
duration [5]
Not limited Not limited Not limited Upper limit of 12 (max. 24) 
months in inflammatory 
diseases (calcineurin inhibitor-
induced nephrotoxicity and 
increased carcinogenesis) [87]
Not limited
Interruption Yes Yes Yes Yes Yes
Use in HBV 
patients [72]
Possible, with 
gastroenterology
Possible, with 
gastroenterology
Possible, with 
gastroenterology
Possible, with gastroenterology Data insufficient
Use in HCV 
patients [88]
Not recommended Second line, with 
gastroenterology
Data insufficient Third line, with 
gastroenterology
Data insufficient
Use in HIV 
patients [89]
Third line, with infectiology Second line, with 
infectiology
Data insufficient Third line, with infectiology Data insufficient
Use in latent 
tuberculosis 
patients
Possible, with infectiology Possible, with infectiology Possible, with infectiology Possible, with infectiology Data insufficient
Clinical 
evaluation
PASI (PrecisePASI for lower BSA ranges), DLQI after 12 and 24 weeks [24, 106, 107]
p.o. = Per os; s.c. = subcutaneously; h = hour; CHF = Swiss francs; PASI = Psoriasis Area and Severity Index; BSA = body surface area; DLQI = Dermatology Life Quality Index; 
HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus.
Table 16 (continued)
D
ow
nl
oa
de
d 
by
: 
Sp
ita
l N
et
z 
Be
rn
 A
G
   
   
   
   
   
   
   
   
   
   
   
   
16
1.
62
.2
52
.4
0 
- 1
/1
7/
20
17
 3
:5
1:
46
 P
M
 Swiss S1 Guidelines on Psoriasis Dermatology 2016;232:385–406
DOI: 10.1159/000445681
401
 Anti-TNF-α Anti-p40 (IL-12/23) Anti-IL-17A
E nbrel® Remicade® Humira® Stelara® Cosentyx®
Median onset 
of effect [5]
4 – 8 weeks 1 – 4 weeks 4 – 8 weeks 2 – 4 weeks [92, 93] 2 – 3 weeks [54]
PASI75 (few head-
to-head studies) 
[17, 94, 106, 107]
Week 12: 43.5%
Week 24: 55.3%
(50 mg twice a week)
Week 10: 75 – 80% [95, 96]
Week 24: 69.2%
Week 16: 71 – 79.6% [75, 
97]
Week 24: 63.3% [92, 97]
Week 12/24: 
– 45 mg: 70.1/75.5%
– 90 mg: 66.5/75.0%
Week 12: 75 – 87%
Week 16: 86%
(300 mg)
PASI90 (few head-
to-head studies)
[57, 98]
Week 12: 19.3% 
Week 24: 27.8%
(50 mg twice a week)
Week 10: 49.5%
Week 24: 50.6%
Week 16: 36.5%
Week 24: 45.7%
Week 12/24: 
– 45 mg: 47.2/58.2%
– 90 mg: 35.5/48.5%
Week 12: 59.2% 
Week 16: 69.8%
(300 mg) [54]
Contraindications 
[17]
Absolute: active tuberculosis, active chronic hepatitis B, significant active infection, pregnancy 
or breast-feeding (relative in ETA), heart failure (NYHA grade III/IV), hypersensitivity to 
drug
Relative: hepatitis C, malignancies (apart from successfully treated nonmelanoma skin cancer 
and cervical dysplasia) or lymphoproliferative disorders, live attenuated vaccines, 
demyelinating diseases, >200 PUVA treatments (especially if followed by cyclosporine use); 
further: ETA: HIV or AIDS, congestive heart failure (NYHA grade I or II); IFX: hepatobiliary 
disorders; ADA: history of recurrent infection, underlying conditions predisposing to 
infections, patients living in geographical areas where tuberculosis and histoplasmosis are 
widespread, concomitant systemic lupus erythematosus, localized infections, latent 
tuberculosis
Absolute: hypersensitivity to 
the active substance or to 
any of the excipients, 
clinically important active 
infection including 
untreated latent tuberculosis; 
relative: malignancies (apart 
from successfully treated 
nonmelanoma skin cancer 
and cervical dysplasia) and 
lymphoproliferative 
disorders, pregnancy, live 
vaccines
Absolute: active tuberculosis 
or acute, severe infections, 
live vaccines, active chronic 
hepatitis B, pregnancy/
breast-feeding
Relative: Crohn’s disease 
(monitor closely), 
malignancies (beside basal 
cell carcinoma), and 
lymphoproliferative 
disorders
Antidrug
antibodies [99]
1.1 – 18%, no association with 
clinical loss of response
19.5 – 51.5%, association 
with clinical loss of response
6 – 46%, association with 
clinical loss of response
3.8 – 5.1%, association with 
clinical loss of response [92, 
93]
<1%, no association with 
clinical loss of response
Potential side
effects [30]
(selection, not 
grouped by 
frequency)
Local reactions to injection 
site, e.g. in latex allergy, upper 
respiratory tract infections, 
pruritus, (thrombo)cytopenia, 
urticaria, angioedema, lupus, 
multiple sclerosis, vasculitis, 
drug rash; in 0.5% paradoxical 
psoriasis, in 0.1% lupus-like 
reactions
Up to 20% infusion 
reactions; viral and bacterial 
infections including 
reactivation of opportunistic 
infections, fever, serum 
sickness, autoantibodies, 
lupus-like syndrome, 
cytopenia, headache, 
vertigo, exacerbation of 
demyelinating disorders, 
flush, gastrointestinal 
conditions, elevated liver 
values, spinocellular skin 
cancer, drug rash, pruritus, 
paradoxical psoriasis
Local reactions at injection 
site, rarely angioedema, 
vertigo, headache, fever, 
fatigue, bacterial and viral 
infections, cytopenia, 
elevation of liver enzymes, 
lupus-like syndrome, 
neurological symptoms 
including paresthesias, 
multiple sclerosis, paralysis 
of the face, lymphoma, 
solid organ tumors, 
spinocellular skin cancer, 
malignant melanoma
Local reaction at the 
injection site, upper 
respiratory tract infection, 
cellulitis, depression, vertigo, 
headache, pharyngolaryngeal 
pain, diarrhea, pruritus, back 
pain, myalgia, fatigue [90]
Upper respiratory tract 
infections, rhinitis, 
rhinorrhea, oral herpes, 
diarrhea, urticaria, 
neutropenia, oral candidiasis, 
tinea pedis, esophageal 
candidiasis, conjunctivitis, 
elevated transaminases, 
elevated bilirubin, 
immunogenicity, 
exacerbation of Crohn’s 
disease, anaphylaxis, 
staphylococcal skin 
infections
Use in HBV-
infected patients
[100, 101]
Yes, during continued use of HBV therapy started 3 months before biological therapy; HBV 
DNA and liver function tests every 2 months, together with gastroenterology; most evidence 
for ETA
Case-specific decision Data insufficient
Use in HCV-infected 
patients [100, 101]
Yes, monitor liver function and HCV RNA, treat together with gastroenterology; most 
evidence for ETA
Case-specific decision Data insufficient
Use in HIV-infected 
patients
Possible, case-specific decision, together with infectiology [89, 102] Data insufficient Data insufficient
Use in latent 
tuberculosis patients
Requires therapy with isoniazid and vitamin B6 for 9 months, start of biological possible after 1 month [103, 104]; ETA potentially safer than ADA and IFX 
[105]
Interactions Anakinra, abatacept None known Dose of drugs which interact 
with CYP450 3A4, 1A2 or 
2C9 should be evaluated
Costs per year (first 
year including 
induction phase)
[30], CHF
24,516 (30,174) 
(50 mg twice a week until
week 12, then every week)
19,941 (29,912)
(5 mg/kg in 80-kg person)
21,232 (22,866) 17,724 (22,156) 
(45 mg = 90 mg)
22,314 (26,033)
Interruption Yes Not recommended Possibly Not recommended Data insufficient
Risk of cancer Cancer risk is slightly elevated for nonmelanoma skin cancers and potentially hematological cancers [106], but not other 
tumors [107]
Data insufficient
Clinical 
evaluation
PASI (PrecisePASI for lower BSA ranges), DLQI after 12 and 24 weeks [24, 106, 107]
s.c. = Subcutaneously; i.v. = intravenously; CHF = Swiss francs; PASI = Psoriasis Area and Severity Index; BSA = body surface area; DLQI = Dermatology Life Quality Index;
HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus; TNFα = tumor necrosis factor alpha; ETA = etanercept; ADA = adaliumumab; IFX = inflix-
imab; UST = ustekinumab; SEC = secukinumab; MTX = methotrexate; CsA = cyclosporin A.
Table 17 (continued)
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 Appendix 1: Dermatology Life Quality Index 
1. Over the last week, how itchy, sore, 
painful or stinging has your skin
 been?
 of your skin?
Very much 
A lot  
A little  
Not at all 
Very much 
A lot  
A little  
Not at all 
Very much 
A lot  
A little  
Not at all 
Very much 
A lot  
A little  
Not at all 
Very much 
A lot  
A little  
Not at all 
Very much 
A lot  
A little  
Not at all 
2.  Over the last week, how embarrassed
 or self-conscious have you been because 
3.  Over the last week, how much has your
 skin interfered with you going
shopping or looking after your home or
garden?  Not relevant 
4.  Over the last week, how much has your 
 skin influenced the clothes
 you wear?
 Not relevant 
5.  Over the last week, how much has your 
 skin affected any social or
leisure activities?
 Not relevant 
6.  Over the last week, how much has your
 skin made it difficult for
 you to do any sport? 
 Not relevant 
7.  Over the last week, has your skin prevented
 you from working or studying?  Not relevant 
 If ‘No’, over the last week how much has 
 your skin been a problem at
work or studying? Not at all 
8.  Over the last week, how much has your
 skin created problems with your 
partner or any of your close friends
 or relatives?  Not relevant 
9.  Over the last week, how much has your
 skin caused any sexual
difficulties?
 Not relevant 
10.  Over the last week, how much of a
 problem has the treatment for your
 skin been, for example by making 
 your home messy, or by taking up time?  Not relevant 
Please check you have answered EVERY question. Thank you.
©A.Y. Finlay, G.K. Khan, April 1992, www.dermatology.org.uk. This must not be copied without the permission of the authors.
The aim of this questionnaire is to measure how much your skin problem has affected your life 
OVER THE LAST WEEK.  Please tick րone box for each question.
DLQI
Hospital No.: Date: Score:
Name: Diagnosis:
Address:
Yes
A lot
A little  
Not at all 
A lot
Very much 
A little  
Not at all 
A lot
Very much 
A little  
Not at all 
A lot
Very much 
A little
No
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 Appendix 2: PEST Score 
Psoriasis Epidemiology Screening Tool (PEST)
Screening questionnaire for psoriasis arthritis in psoriatic patients 
No Yes
Have you ever had a swollen joint (or joints)?
Has a doctor ever told you that you have arthritis?
Do your fingernails or toenails have holes or pits?  
Have you had pain in your heel?
Have you had a finger or toe that was completely 
swollen and painful for no apparent reason?
In the drawing below, please tick the joints that have caused you 
discomfort (i.e. stiff, swollen, or painful joints): 
From Helliwell [70].
RIGHT
Shoulder Shoulder
LEFT
Elbow Elbow
Wrist
Thumb Thumb
Hand/
Fingers
Upper
Back
Lower
Back Wrist
Hand/
Fingers
Knee Knee
Ankle Ankle
Foot/Toes Foot/Toes
Neck
Hip
Waist level
Hip
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